)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Hofseth BioCare
Hofseth BioCare (HBC) investor relations material
Hofseth BioCare Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary21 Aug, 2026
Executive summary
Q2 2026 marked a pivotal quarter with structurally higher prices, improved yields, and a right-sized cost base, resulting in operational EBITDA at break-even and a restored balance sheet following a private placement.
Despite processing 44% less raw material year-over-year, total operating revenue held at NOK 65.7 million, with gross margin rising to 50%.
Commercial repricing led to over 100% increases in average selling prices for key products, and B2B Consumer Health revenue grew 72% sequentially.
The company secured a global exclusive agreement for ProGoⓇ in network marketing and expanded its retail footprint to over 20 territories.
Financial highlights
Total operating revenue: NOK 65.7 million (Q2 2025: NOK 68.4 million).
Gross margin: 50.0% (Q1 2026: 43.5%).
Operational EBITDA: NOK -0.6 million (Q2 2025: NOK 1.3 million), a NOK 17 million improvement from Q1 2026.
EBITDA: NOK -2.7 million (Q2 2025: NOK -5.4 million).
EBIT: NOK -12.9 million (Q2 2025: NOK -14.9 million).
Profit before tax: NOK -23.2 million (Q2 2025: NOK -25.1 million).
Cash and cash equivalents: NOK 108.0 million at quarter-end (Q2 2025: NOK 68.0 million).
Equity ratio: -7.4% (Q2 2025: 0.1%).
Outlook and guidance
The company expects continued commercial momentum, with structurally higher prices and improved profitability as production returns to full capacity by end of Q3 2026.
Full-year prognosis for both sales and margin remains unchanged, with B2C profitability expected to improve in 2027 following supply model transition.
R&D pipeline includes key clinical readouts in H2 2026 and new product launches in late 2026 and 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hofseth BioCare
- Sales surged, but losses persisted as a NOK 144m debt conversion strengthened the balance sheet.HBC
Q4 2023 - Gross margin expanded and equity was restored post-period, positioning for profitable growth.HBCQ1 2026
- Q4 2025 saw record production, strong B2B growth, and improved liquidity despite negative EBITDA.HBCQ4 2025
- Record production and margin gains offset lower sales; outlook remains positive after recapitalization.HBCQ3 2025
- Gross margin rose to 46% and operational EBITDA turned positive despite lower Q2 revenues.HBCQ2 2025
- Q3 revenue up 36% year-over-year, with strong B2B growth and improved outlook for 2025.HBCQ3 2024
- Record sales growth in Q2, but margins and profitability remain under pressure.HBCQ2 2024
- Q1 2025 saw 15% revenue growth, strong B2B gains, and record production despite margin pressure.HBCQ1 2025
- 35% revenue growth, margin gains, and U.S. expansion set stage for 2025 acceleration.HBCQ4 2024
Next Hofseth BioCare earnings date
Q3 20266 Nov, 2026
Hofseth BioCare
Next Hofseth BioCare earnings date
Q3 20266 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Hofseth BioCare ASA is a biotechnology company that focuses on the production of high-value ingredients derived from fish. The company develops and commercializes sustainable biomarine products for human and pet health. Its product portfolio includes bioactive peptides, oils, calcium, and proteins, which are used in a variety of industries, including dietary supplements, clinical nutrition, and functional foods. Hofseth BioCare emphasizes utilizing fresh raw materials and applying a gentle enzymatic hydrolysis process to retain the nutritional properties of the fish. The company is headquartered in Ålesund, Norway, and its shares are listed on the Oslo Stock Exchange.